TRANSCEND-T2D-1 Results by Dose (40 Weeks) The 16.8% weight loss in this population is substantially below TRIUMPH-1's 28.3% a pattern consistent across the GLP-1 drug class, where type 2 diabetes reduces the magnitude of weight loss compared to non-diabetic obesity populations
Physicians need to exercise caution with patients who have experienced pancreatitis or serious gut issues
These effects may interfere with post-operative recovery and increase complication risk
U.S.-SYNTHESIZED PEPTIDES | 99% COA-VERIFIED PURITY | 6 INDEPENDENT TESTING | BATCH-LEVEL TRACEABILITY No products in the cart
At Vive Ageless Weight Loss Center, our medical professionals customize GLP-1 therapies like Ozempic as part of a comprehensive, individualized weight-loss program
Back DiMarchi, R Efendic, S (1997) 'Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity', US Patent US6191102B1.Back Drucker, DJ, Habener, JF, Holst, JJ (1 Dec 2017) 'Discovery, characterization, and clinical development of the glucagon-like peptides', Journal of Clinical Investigation , 127/12, 4217-27